" data-medium-file="https://3druck.com/wp-content/uploads/2026/03/CollPlant_BioFlex_Bioink-300x169.jpg" data-large-file="https://3druck.com/wp-content/uploads/2026/03/CollPlant_BioFlex_Bioink-1024x576.jpg" /> Im 3D-Bioprinting entscheidet die Bioink-Formulierung oft über den Unterschied zwischen einem sauber gedruckten Prototyp und einem belastbaren Gewebemodell. Gerade bei Digital Light Processing (DLP) mit photochemischer Vernetzung müssen Viskosität, Photoinitiator-System und Polymernetzwerk so zusammenpassen, dass hohe Auflösung möglich ist, ohne Zellen oder Strukturen durch zu sprödes Material zu gefährden. CollPlant bringt dafür mit BioFlex ein […] Der Beitrag CollPlant liefert BioFlex: rhCollagen-Kit für DLP-Bioprinting mit abstimmbarer Mechanik erschien zuerst auf 3Druck.com - The Independent AM Magazine.

Reported Monday, Oct 27 - 7:11am EDT (TheFly subscription required to read more.)

CollPlant Biotechnologies has announced a successful $2.6 million private placement to further its innovative regenerative medicine technology and research.

CollPlant Biotechnologies has released its financial results for Q1 2026, highlighting corporate updates in regenerative medicine and aesthetics.

CollPlant outlines its future plans following the end of its partnership with AbbVie, focusing on new developments in aesthetic medicine and revenue growth.

CollPlant Biotechnologies reveals its financial results for 2025, highlighting significant advancements in regenerative medicine and aesthetic products, while expanding its market reach.

CollPlant Biotechnologies has received a notice from Nasdaq due to its share price falling below the minimum bid requirement, sparking compliance issues.

CollPlant Biotechnologies has launched a redesigned corporate website, aiming to enhance accessibility and engagement for investors and partners through improved information flow.

CollPlant Biotechnologies, recognized for its innovative biotechnological solutions in medical aesthetics, will announce its financial results for 2025 on March 26, 2026, prior to U.S. market opening.

CollPlant Biotechnologies announces the successful patent allowance for their photocurable dermal filler technology in South Korea, marking a significant milestone.

CollPlant announces the launch of BioFlex, a ready-to-print bioprinting kit that enhances the creation of complex tissue models, crucial for regenerative medicine.

CollPlant Biotechnologies unveils a $2 million direct offering to boost growth in regenerative medicine, focusing on innovative rhCollagen products.

CollPlant Biotechnologies has released its financial results for the third quarter of 2025, highlighting growth in rhCollagen sales and a new logistics partnership in North America.

CollPlant Biotechnologies has announced the opening of a new logistics center in the U.S., enhancing their distribution of rhCollagen and BioInk products for markets in the U.S. and Canada.

A recent study by Technion reveals CollPlant's rhCollagen-based bioink, Collink.3D™, outmatching Matrigel® in tissue formation. Promoting eco-friendly practices in engineering.

Mayo Clinic researchers have developed a groundbreaking 3D bioprinted human skin model using innovative plant-derived bioink. This advancement offers an ethical alternative to animal testing for medical research.

CollPlant Biotechnologies announces encouraging outcomes from its non-clinical studies on a groundbreaking photocurable dermal filler, paving the way for clinical trials.

CollPlant Biotechnologies announces expanded European distribution for its Vergenix STR product, aimed at enhancing tendon healing across multiple indications.

CollPlant Biotechnologies will present groundbreaking advancements in biofabrication at the upcoming international conference in Warsaw, Poland.

Join CollPlant Biotechnologies as they present groundbreaking advancements in regenerative medicine at the 27th Global Investment Conference in New York.

CollPlant Biotechnologies reveals its financial results for Q2 2025 and announces significant advancements in its regenerative medicine products and corporate strategy.

CollPlant Biotechnologies has announced that it will disclose its financial results for the second quarter on August 20, 2025, before market opening.

CollPlant Biotechnologies has appointed Bowman Bagley as VP of North America Commercial Operations to drive growth and expand market presence.

CollPlant Biotechnologies enhances collaboration with STEMCELL Technologies to broaden applications for its rhCollagen in regenerative medicine and aesthetics.